Basic and clinical studies on tazobactam/piperacillin in respiratory infections

H. Fukuhara, J. Inadome, T. Kakazu, H. Nakamura, H. Kaneshima, A. Saito, Nobuchika Kusano, I. Nakasone, Y. Furgen, S. Taira, S. Hokama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), a new formulation of the β-lactamase inhibitor tazobactam (TAZ) and piperacillin (PIPC), and the following results were obtained. 1. Antimicrobial activity: The minimum inhibitory concentrations (MIC) of TAZ/PIPC against a total of 257 clinically isolated strains of 12 species were measured and compared with those of PIPC, clavulanic acid/ticarcillin (CVA/TIPC), cefotiam (CTM) and cefoperazone (CPZ), using the MIC2000 System (Dynatech Laboratories). TAZ/PIPC showed stronger bactericidal activity than PIPC and CVA/TIPC, and much stronger activity than CTM or CPZ against gram-positive bacteria, but CPZ showed much stronger activity than TAZ/PIPC against gram-negative bacteria. 2. Clinical study results: TAZ/PIPC (5 g per day) was given to three patients with pneumonia and one with acute bronchitis, for 4 ~ 15 days. Clinical response was excellent in two patients and good in two patients. Mild fever was observed in one patient. Abnormal laboratory findings were observed in one patient with eosinophilia and elevation of GPT, but these were transient. From the above results, we consider TAZ/PIPC to be a useful antibiotic for the treatment of respiratory tract infection.

Original languageEnglish
Pages (from-to)476-481
Number of pages6
JournalChemotherapy
Volume42
Issue numberSUPPL. 2
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Respiratory Tract Infections
Cefoperazone
Cefotiam
Piperacillin
Bronchitis
Eosinophilia
Gram-Positive Bacteria
Microbial Sensitivity Tests
tazobactam drug combination piperacillin
Clinical Studies
Gram-Negative Bacteria
Pneumonia
Fever
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fukuhara, H., Inadome, J., Kakazu, T., Nakamura, H., Kaneshima, H., Saito, A., ... Hokama, S. (1994). Basic and clinical studies on tazobactam/piperacillin in respiratory infections. Chemotherapy, 42(SUPPL. 2), 476-481.

Basic and clinical studies on tazobactam/piperacillin in respiratory infections. / Fukuhara, H.; Inadome, J.; Kakazu, T.; Nakamura, H.; Kaneshima, H.; Saito, A.; Kusano, Nobuchika; Nakasone, I.; Furgen, Y.; Taira, S.; Hokama, S.

In: Chemotherapy, Vol. 42, No. SUPPL. 2, 1994, p. 476-481.

Research output: Contribution to journalArticle

Fukuhara, H, Inadome, J, Kakazu, T, Nakamura, H, Kaneshima, H, Saito, A, Kusano, N, Nakasone, I, Furgen, Y, Taira, S & Hokama, S 1994, 'Basic and clinical studies on tazobactam/piperacillin in respiratory infections', Chemotherapy, vol. 42, no. SUPPL. 2, pp. 476-481.
Fukuhara H, Inadome J, Kakazu T, Nakamura H, Kaneshima H, Saito A et al. Basic and clinical studies on tazobactam/piperacillin in respiratory infections. Chemotherapy. 1994;42(SUPPL. 2):476-481.
Fukuhara, H. ; Inadome, J. ; Kakazu, T. ; Nakamura, H. ; Kaneshima, H. ; Saito, A. ; Kusano, Nobuchika ; Nakasone, I. ; Furgen, Y. ; Taira, S. ; Hokama, S. / Basic and clinical studies on tazobactam/piperacillin in respiratory infections. In: Chemotherapy. 1994 ; Vol. 42, No. SUPPL. 2. pp. 476-481.
@article{8b7810e600004b05a13e4b929e85b3cb,
title = "Basic and clinical studies on tazobactam/piperacillin in respiratory infections",
abstract = "We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), a new formulation of the β-lactamase inhibitor tazobactam (TAZ) and piperacillin (PIPC), and the following results were obtained. 1. Antimicrobial activity: The minimum inhibitory concentrations (MIC) of TAZ/PIPC against a total of 257 clinically isolated strains of 12 species were measured and compared with those of PIPC, clavulanic acid/ticarcillin (CVA/TIPC), cefotiam (CTM) and cefoperazone (CPZ), using the MIC2000 System (Dynatech Laboratories). TAZ/PIPC showed stronger bactericidal activity than PIPC and CVA/TIPC, and much stronger activity than CTM or CPZ against gram-positive bacteria, but CPZ showed much stronger activity than TAZ/PIPC against gram-negative bacteria. 2. Clinical study results: TAZ/PIPC (5 g per day) was given to three patients with pneumonia and one with acute bronchitis, for 4 ~ 15 days. Clinical response was excellent in two patients and good in two patients. Mild fever was observed in one patient. Abnormal laboratory findings were observed in one patient with eosinophilia and elevation of GPT, but these were transient. From the above results, we consider TAZ/PIPC to be a useful antibiotic for the treatment of respiratory tract infection.",
author = "H. Fukuhara and J. Inadome and T. Kakazu and H. Nakamura and H. Kaneshima and A. Saito and Nobuchika Kusano and I. Nakasone and Y. Furgen and S. Taira and S. Hokama",
year = "1994",
language = "English",
volume = "42",
pages = "476--481",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Basic and clinical studies on tazobactam/piperacillin in respiratory infections

AU - Fukuhara, H.

AU - Inadome, J.

AU - Kakazu, T.

AU - Nakamura, H.

AU - Kaneshima, H.

AU - Saito, A.

AU - Kusano, Nobuchika

AU - Nakasone, I.

AU - Furgen, Y.

AU - Taira, S.

AU - Hokama, S.

PY - 1994

Y1 - 1994

N2 - We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), a new formulation of the β-lactamase inhibitor tazobactam (TAZ) and piperacillin (PIPC), and the following results were obtained. 1. Antimicrobial activity: The minimum inhibitory concentrations (MIC) of TAZ/PIPC against a total of 257 clinically isolated strains of 12 species were measured and compared with those of PIPC, clavulanic acid/ticarcillin (CVA/TIPC), cefotiam (CTM) and cefoperazone (CPZ), using the MIC2000 System (Dynatech Laboratories). TAZ/PIPC showed stronger bactericidal activity than PIPC and CVA/TIPC, and much stronger activity than CTM or CPZ against gram-positive bacteria, but CPZ showed much stronger activity than TAZ/PIPC against gram-negative bacteria. 2. Clinical study results: TAZ/PIPC (5 g per day) was given to three patients with pneumonia and one with acute bronchitis, for 4 ~ 15 days. Clinical response was excellent in two patients and good in two patients. Mild fever was observed in one patient. Abnormal laboratory findings were observed in one patient with eosinophilia and elevation of GPT, but these were transient. From the above results, we consider TAZ/PIPC to be a useful antibiotic for the treatment of respiratory tract infection.

AB - We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), a new formulation of the β-lactamase inhibitor tazobactam (TAZ) and piperacillin (PIPC), and the following results were obtained. 1. Antimicrobial activity: The minimum inhibitory concentrations (MIC) of TAZ/PIPC against a total of 257 clinically isolated strains of 12 species were measured and compared with those of PIPC, clavulanic acid/ticarcillin (CVA/TIPC), cefotiam (CTM) and cefoperazone (CPZ), using the MIC2000 System (Dynatech Laboratories). TAZ/PIPC showed stronger bactericidal activity than PIPC and CVA/TIPC, and much stronger activity than CTM or CPZ against gram-positive bacteria, but CPZ showed much stronger activity than TAZ/PIPC against gram-negative bacteria. 2. Clinical study results: TAZ/PIPC (5 g per day) was given to three patients with pneumonia and one with acute bronchitis, for 4 ~ 15 days. Clinical response was excellent in two patients and good in two patients. Mild fever was observed in one patient. Abnormal laboratory findings were observed in one patient with eosinophilia and elevation of GPT, but these were transient. From the above results, we consider TAZ/PIPC to be a useful antibiotic for the treatment of respiratory tract infection.

UR - http://www.scopus.com/inward/record.url?scp=0028046905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028046905&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028046905

VL - 42

SP - 476

EP - 481

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 2

ER -